RETACRIT
Biological
PFIZER INC.
Total Payments
$107,913
Transactions
356
Doctors
281
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,400 | 1 | 1 |
| 2023 | $4,208 | 4 | 4 |
| 2022 | $21,670 | 14 | 4 |
| 2021 | $162.19 | 8 | 7 |
| 2020 | $139.92 | 9 | 8 |
| 2019 | $331.52 | 21 | 21 |
| 2018 | $80,001 | 299 | 246 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,570 | 28 | 59.8% |
| Unspecified | $28,770 | 19 | 26.7% |
| Consulting Fee | $9,914 | 3 | 9.2% |
| Food and Beverage | $4,494 | 305 | 4.2% |
| Travel and Lodging | $165.27 | 1 | 0.2% |
Payments by Type
General
$79,143
337 transactions
Research
$28,770
19 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| BIOSIMILARS I I CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $12,070 | 4 |
| EPOETIN ZETA MULTI PRODUCT PRINABEREL INFLIXIMAB HOSPIRA ADALIMUMAB PFIZER INFLIXIMAB PFIZER CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,600 | 3 |
| EPOETIN ZETA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,200 | 3 |
| A PHASE 1 OPENLABEL RANDOMIZED SINGLE DOSE CROSSOVER STUDY EVALUATING THE PHARMACOKINETICS OF EPOETIN FOLLOWING ADMINISTRATION OF EPOETIN HOSPIRA MULTIPLE DOSE VIAL MDV PRODUCT COMPARED TO EPOETIN HOSPIRA SINGLE DOSE VIAL SDV PRODUCT AS SUBCUTANEOUS INJECTION TO NORMAL HEALTHY SUBJECTS | PFIZER INC. | $1,500 | 0 |
| ADALIMUMAB PFIZER EPOETIN ZETA INFLIXIMAB HOSPIRA INFLIXIMAB PFIZER PRINABEREL MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
Top Doctors Receiving Payments for RETACRIT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Specialist | Dallas, TX | $14,160 | 9 |
| , M.D | Hematology & Oncology | Rock Hill, SC | $7,191 | 3 |
| , MD | Nephrology | Indianapolis, IN | $7,013 | 3 |
| , MD | Medical Oncology | New York, NY | $6,500 | 1 |
| , M.D | Specialist | Dallas, TX | $6,490 | 5 |
| , MD | Rheumatology | Beckley, WV | $6,490 | 5 |
| , M.D | Specialist | Great Neck, NY | $3,900 | 2 |
| , M.D., PHARM.D., FCP | Pharmacist | Wilmette, IL | $3,900 | 2 |
| , M.D | Hematology & Oncology | Durham, NC | $3,800 | 1 |
| , MD | Hematology | Kansas City, MO | $3,800 | 1 |
| David Reardon | Hematology & Oncology | Boston, MA | $3,800 | 1 |
| , M.D | Medical Oncology | Houston, TX | $3,800 | 1 |
| , M.D | Nephrology | Franklin, TN | $3,200 | 1 |
| , M.D | Internal Medicine | Stanford, CA | $3,200 | 1 |
| , MD | Nephrology | Danville, VA | $3,200 | 1 |
| , M.D | Specialist | Plantation, FL | $3,200 | 1 |
| , MD | Nephrology | Houston, TX | $3,200 | 1 |
| , MD | Internal Medicine | Worcester, MA | $3,200 | 1 |
| , MD, MPH | Internal Medicine | West Hollywood, CA | $3,200 | 1 |
| , M.D | Nephrology | Augusta, GA | $3,200 | 1 |
| Unknown | — | Garden City, NY | $1,500 | 1 |
| , MD | Gastroenterology | Philadelphia, PA | $1,400 | 1 |
| , M.D., PHD | Medical Oncology | New Haven, CT | $1,270 | 2 |
| , MD | Hematology & Oncology | Orlando, FL | $1,270 | 2 |
| , M.D | Nephrology | Bronx, NY | $700.00 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $107,364
- PFIZER PHARMACEUTICALS LLC $376.51
- HOSPIRA, INC. $112.17
- ARRAY BIOPHARMA INC $59.58
Product Information
- Type Biological
- Total Payments $107,913
- Total Doctors 281
- Transactions 356
About RETACRIT
RETACRIT is a biological associated with $107,913 in payments to 281 healthcare providers, recorded across 356 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2018 to 2024. In 2024, $1,400 was paid across 1 transactions to 1 doctors.
The most common payment nature for RETACRIT is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($64,570, 59.8% of total).
RETACRIT is associated with 5 research studies, including "BIOSIMILARS I I CLINICAL PUBLICATION PROGRAM" ($12,070).